[Lamotrigine and the skin].
We report a patient with personality disorder and depression who developed a reversible macular rash 10 days after starting lamotrigine (LTG). We discuss the safety profile of LTG, risk factors for adverse reactions of the skin, the management of risk reduction of LTG - induced skin reactions and the possibility of a controlled reexpostion of patients with benign LTG - associated rash.
Rätz Bravo
A E
AE
Abteilung für klinische Pharmakologie und Toxikologie und Regionales Pharmacovigilance-Zentrum Basel, Universitätsspital Basel. raetza@uhbs.ch
Zimmermann
T
T
Haschke
M
M
D000328:Adult; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy*; D003937:Diagnosis, Differential; D007174:Disruptive, Impulse Control, and Conduct Disorders / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000077213:Lamotrigine; D008140:Lorazepam / Q000009:adverse effects / Q000627:therapeutic use; D014227:Triazines / Q000009:adverse effects* / Q000627:therapeutic use
D014151:Anti-Anxiety Agents; D000927:Anticonvulsants; D014227:Triazines; D008140:Lorazepam; D000077213:Lamotrigine
Lamotrigin und die Haut.